Taxanes, particularly docetaxel (DTX), has been widely used for combination therapy of
head and neck squamous cell carcinoma (HNSCC). For locally advanced unresectable …

Background There are still few data on the activity and safety of cetuximab-based salvage
chemotherapy after immunotherapy (SCAI) in patients with squamous cell cancer of the …

Background Immune checkpoint inhibitors are widely used in recurrent and/or metastatic
head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response …

Objective Although nivolumab treatment is effective in extending the overall survival (OS) in
patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M …

The immune checkpoint inhibitor (ICI), nivolumab, has revolutionised the treatment of
recurrent and metastatic oral cancer. However, the response rate to ICIs remains low, and …

Immunotherapy with PD-1 inhibitors monotherapy or combined with chemotherapy
comprises the first-line palliative treatment for patients with recurrent or metastatic head and …

Background Significant immune-related adverse events (irAEs) requiring therapy
discontinuation sometimes occur. The influence of discontinuation on disease control after …

Abstract Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results
against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or …

Background The application of anti‐programmed death‐1 (PD‐1) therapies for recurrent or
metastatic head and neck squamous cell carcinoma (HNSCC) has found promising results …

There has been a major resurgence of interest in immune-based approaches to treat cancer,
based largely on the success of checkpoint inhibitors (anti–cytotoxic T-lymphocyte …